Identification of antigenic peptides from novel renal cancer stem-like cell antigen, DNAJB8

Nishizawa, Satoshi; Hirohashi, Yoshihiko; Kusumoto, Hiroki; Wakamiya, Takahito; Iguchi, Takashi; Yamashita, Shimpei; Iba, Akinori; Kikkawa, Kazuro; Kohjimoto, Yasuo; Torigoe, Toshihiko; Hara, Isao

doi:10.1016/j.bbrc.2017.10.146

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DNAJB8 might have oncogenic potential since it strongly suppresses misfolded protein aggregation. This HSP plays a role in the maintenance of RCC CSCs as its targeting fully blocked tumor formation in mice, suggesting that it may be a target for immunotherapy [115,116] (Table 1). Tumorigenicity [115] MicroRNAs (miRNAs) regulates gene expression and their roles in CSCs have been elucidated for some cancers.…”

Section: Renal Cancer Stem Cellsmentioning

confidence: 99%

Cancer Stem Cells in Renal Cell Carcinoma: Origins and Biomarkers

Lasorsa,

Rutigliano,

Milella

et al. 2023

IJMS

View full text Add to dashboard Cite

The term “cancer stem cell” (CSC) refers to a cancer cell with the following features: clonogenic ability, the expression of stem cell markers, differentiation into cells of different lineages, growth in nonadhesive spheroids, and the in vivo ability to generate serially transplantable tumors that reflect the heterogeneity of primary cancers (tumorigenicity). According to this model, CSCs may arise from normal stem cells, progenitor cells, and/or differentiated cells because of striking genetic/epigenetic mutations or from the fusion of tissue-specific stem cells with circulating bone marrow stem cells (BMSCs). CSCs use signaling pathways similar to those controlling cell fate during early embryogenesis (Notch, Wnt, Hedgehog, bone morphogenetic proteins (BMPs), fibroblast growth factors, leukemia inhibitory factor, and transforming growth factor-β). Recent studies identified a subpopulation of CD133+/CD24+ cells from ccRCC specimens that displayed self-renewal ability and clonogenic multipotency. The development of agents targeting CSC signaling-specific pathways and not only surface proteins may ultimately become of utmost importance for patients with RCC.

show abstract

Section: Renal Cancer Stem Cellsmentioning

confidence: 99%

Cancer Stem Cells in Renal Cell Carcinoma: Origins and Biomarkers

Lasorsa,

Rutigliano,

Milella

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…It is plausible to hypothesize that combining primed CD8+ cells with traditional chemotherapy could lead to killing of both bulk and CSC populations in tumors . Continuing to identify antigen specific to CSCs over bulk tumors, such as BORIS sf6 in cervical cancer which can be targeted using a BORIS C34_24(9)‐specific cytotoxic T cell and DNAJB8, an HSP40 family member implicated in the formation of renal CSCs are important future directions for the success of immunotherapy. Other novel approaches include the CD133 DC immunotherapy ICT‐121, which showed promising phase 1 data by mounting a cytotoxic T‐cell response against CD133+ CSCs, as well as ALDH1 high presenting DCs which have demonstrated promising results in preclinical melanoma models .…”

Section: Potential For Immunotherapy Treatment Of Cscsmentioning

confidence: 99%

Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success

Desai

Yan

Gerson

2018

Stem Cells Translational Medicine

155

126

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are a subpopulation of cells within tumors that possess the stem cell characteristics of self‐renewal, quiescence, differentiation, and the ability to recapitulate the parental tumor when transplanted into a host. CSCs are correlated with poor clinical outcome due to their contribution to chemotherapy resistance and metastasis. Multiple cell surface and enzymatic markers have been characterized to identify CSCs within a heterogeneous tumor, and here we summarize ongoing preclinical and clinical efforts to therapeutically target these cells and improve patient outcomes. Stem Cells Translational Medicine 2019;8:75–81

show abstract

Identification of antigenic peptides from novel renal cancer stem-like cell antigen, DNAJB8

Cited by 2 publications

References 24 publications

Cancer Stem Cells in Renal Cell Carcinoma: Origins and Biomarkers

Cancer Stem Cells in Renal Cell Carcinoma: Origins and Biomarkers

Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success

Contact Info

Product

Resources

About